OL0 Stock Overview
Develops, manufactures, and sells diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for OL0 from our risk checks.
Devyser Diagnostics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 10.95 |
| 52 Week High | SEK 11.80 |
| 52 Week Low | SEK 6.10 |
| Beta | 0.74 |
| 11 Month Change | -0.91% |
| 3 Month Change | 15.75% |
| 1 Year Change | 77.18% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 30.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| OL0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.9% | -0.7% | -0.02% |
| 1Y | 77.2% | -17.2% | 8.2% |
Return vs Industry: OL0 exceeded the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: OL0 exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| OL0 volatility | |
|---|---|
| OL0 Average Weekly Movement | 5.3% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OL0 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: OL0's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 119 | Fredrik Alpsten | devyser.com |
Devyser Diagnostics AB (publ) develops, manufactures, and sells diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analysis, as well as accessories. Its products are used for targeted cancer treatment to diagnosis genetic diseases and transplant patient follow-up.
Devyser Diagnostics AB (publ) Fundamentals Summary
| OL0 fundamental statistics | |
|---|---|
| Market cap | €185.20m |
| Earnings (TTM) | -€6.21m |
| Revenue (TTM) | €17.23m |
10.8x
P/S Ratio-29.8x
P/E RatioIs OL0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OL0 income statement (TTM) | |
|---|---|
| Revenue | SEK 198.10m |
| Cost of Revenue | SEK 39.60m |
| Gross Profit | SEK 158.50m |
| Other Expenses | SEK 229.90m |
| Earnings | -SEK 71.40m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -4.32 |
| Gross Margin | 80.01% |
| Net Profit Margin | -36.04% |
| Debt/Equity Ratio | 0.1% |
How did OL0 perform over the long term?
See historical performance and comparison